Medical Science News

RSS

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

A*STAR announces fifth major collaboration with Italian research centres and universities

Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .

9 Apr 2010

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Gastric cancer in Mexico is the most frequent gastrointestinal malignant neoplasm. Several precursor conditions, such as chronic gastritis, have been associated with the development of gastric cancer. The gelatinases MMP-2 and MMP-9, members of the metalloproteinase family, are fundamental enzymes in extracellular matrix remodelling. The extracellular matrix is composed of secreted molecules outside cells which provides structural support and regulates cell behaviour.

9 Apr 2010

Effective compound against antibiotic-resistant biofilms

Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria such as the Staphylococcus strain MRSA and Acinetobacter. The compound also re-sentsitizes those bacteria to antibiotics.

9 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

A new discovery raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought. In a new study appearing online in The FASEB Journal, scientists have identified a way to detect the disorder using blood and have discovered that drugs which affect the methylation state of genes could reverse autism's effects.

9 Apr 2010

New methodology helps investigate unfolding of DNA

NYU Langone Medical Center researchers have developed a powerful new method to investigate the discrete steps necessary to turn on individual genes and examine how the process goes wrong in cancer and other diseases. The finding, based on seven years of research and described in the April 9 issue of Molecular Cell, allows scientists to investigate the unfolding of DNA, a process required for gene activation.

9 Apr 2010

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.

9 Apr 2010

Recql5 identified as a tumor suppressor in GI tract

Recql5 is a member of the mammalian RecQ helicase family. Genetic mutations that result in loss of RecQ helicase activity give rise to disorders that are associated with cancer predisposition and premature aging, such as Bloom, Werner, and Rothmund-Thomson syndromes. This class of enzymes is best known for their role in maintaining the integrity of the genome to prevent oncogenic mutations.

9 Apr 2010

Bayer CropScience, Precision BioSciences modify plant genomes using DNE technology

Precision BioSciences Inc., announced today that Bayer CropScience and Precision BioSciences have successfully modified plant genomes using Precision's Directed Nuclease EditorTM technology.

9 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

No link between dyslexia and lack of musical ability

There is no link between a lack of musical ability and dyslexia. Moreover, attempts to treat dyslexia with music therapy are unwarranted, according to scientists in Belgium writing in the current issue of the International Journal of Arts and Technology.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

Combination telaprevir treatment beneficial for retreatment of hepatitis C

A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Medical Science News

Tβ4 therapy for ocular disorders closer to reality

A*STAR announces fifth major collaboration with Italian research centres and universities

Gelatinase B expression enhanced in gastric cancer compared to normal gastric mucosa

Effective compound against antibiotic-resistant biofilms

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

New methodology helps investigate unfolding of DNA

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Recql5 identified as a tumor suppressor in GI tract

Bayer CropScience, Precision BioSciences modify plant genomes using DNE technology

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

No link between dyslexia and lack of musical ability

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

"Nanovaccine" reverses diabetes

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Combination telaprevir treatment beneficial for retreatment of hepatitis C

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News